ClinicalTrials.gg
RecruitingNCT07001332ELEVATE IIIUpdated Oct 9, 2026

ELEVATE High-Risk PCI Pivotal Study

An interventional study of Elevate and Impella in High-Risk Percutaneous Coronary Intervention (High-risk PCI), sponsored by Magenta Medical Ltd.. Recruiting at 33 sites in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Magenta Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years to 88 Years
Sex
All
01

Study summary

The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group. The study is intended to assess the safety and efficacy of the Elevate™ percutaneous Left Ventricular Assist Device System in patients referred to high-risk percutaneous coronary interventions (HR-PCI).

Read the detailed description

The Elevate™ percutaneous Left Ventricular Assist Device System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease. Use of the Elevate™ System in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions.

02

Conditions studied

  • High-Risk Percutaneous Coronary Intervention (High-risk PCI)
03

In context

Lead sponsor

Magenta Medical Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-emergent, percutaneous coronary intervention is planned on at least one stenotic lesion of a native coronary artery or bypass graft (de novo or restenosis).
  2. Baseline (uncorrected) >10.0 g/dl as long as an active source of blood loss has been reasonably excluded.
  3. A heart team that includes an interventional cardiologist and cardiac surgeon has determined that HR- PCI is an appropriate therapeutic option.
  4. Participant signed the .

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure.
  2. Prior stroke with any permanent, significant (mRS>2) neurological deficit, or stroke or within 3 months prior to enrollment.
  3. Any condition or scheduled surgery that will require discontinuation of the antiplatelet and/or anticoagulation therapy within 90 days of the index procedure.
  4. Evidence of left ventricular thrombus.
  5. Aortic valve stenosis/calcification (valve area ≤ 1.5 cm2).
  6. Aortic valve regurgitation (AR) > +2 on a 4-grade scale using transthoracic echocardiography.
  7. Femoral access site incompatibility that precludes placement of either the Treatment or Control device.
  8. Patient on dialysis.
  9. Known or suspected coagulopathy OR abnormal coagulation parameters.
  10. Known allergy, sensitivity or intolerance to nickel.
  11. Infection of the proposed procedural access site; OR suspected systemic active infection, including any fever or known active COVID-19 infection.
  12. Allergy, sensitivity or intolerance to heparin, or contrast media, including known heparin-induced thrombocytopenia (HIT).
  13. Any non-cardiac condition with a \< 12 months.
  14. Subject participation in another drug or device trial (with the exception of post-market registries and observational studies, subject to Sponsor review and approval).
  15. Pregnancy or breast-feeding.
  16. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromise the participant's ability to provide written and/or to comply with study procedures.
  17. Subject belongs to a vulnerable population.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    Elevate

    Subjects receiving the Elevate System

    Device: Elevate

  • Active comparator
    Impella

    Subjects receiving the Impella System

    Device: Impella

Interventions

  • DeviceElevate

    The Elevate System is a catheter- mounted, self-expanding and retrievable, continuous-flow pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta, thus augmenting cardiac output and maintaining systemic arterial pressure during complex/high-risk coronary interventions. Subjects will receive an Elevate prior to their high-risk percutaneous intervention.

  • DeviceImpella

    Subjects will receive an Impella prior to their high-risk percutaneous intervention.

06

What researchers measure

Primary outcomes

  1. A composite of the incidence of major safety and effectiveness parameters.

    A composite of the incidence of: 1. Major Adverse Cardiac and Cerebrovascular Events (MACCE): Death, Myocardial Infarction, Stroke or Transient Ischemic Attack, Unplanned Repeat Revascularization; 2. Major intra-procedural hemodynamic events on Mechanical Circulatory Support: Severe Hypotension, Cardio-Pulmonary Resuscitation or Cardioversion; 3. Major Mechanical Circulatory Support-related access site complications: Vascular Injury Requiring Intervention or Access Site Bleeding.

    Time frame: 30 days

Secondary outcomes

  1. Major Hemolysis during index hospitalization

    Incidence of Major Hemolysis

    Time frame: Perioperative/Periprocedural

  2. Incidence of Bleeding Academic Research Consortium (BARC) Type 3 or Type 5 bleeding events related to the index percutaneous coronary intervention.

    The incidence of bleeding events related to the index percutaneous coronary intervention meeting the definition of Bleeding Academic Research Consortium (BARC) Type 3 or Type 5 bleeding.

    Time frame: Perioperative/Periprocedural

  3. Length of hospital stay

    Length of hospital stay across all enrolled patients

    Time frame: Perioperative/Periprocedural

  4. Length of ICU/CCU stay

    Length of ICU/CCU stay across all enrolled patients

    Time frame: Perioperative/Periprocedural

07

Study locations

33 of 33 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Jun 3, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Mar 16, 2027
CompletionEst.
Sep 16, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • NYU Langone/Bellevue/Long Island · New York, United StatesContact added (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • NYU Langone/Bellevue/Long Island · New York, United StatesContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07001332
Lead sponsor
Magenta Medical Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Jul 25, 2025
Primary completion
Mar 16, 2027 (estimated)
Completion
Sep 16, 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion